NO20084010L - Krystallform av besipirdinklorhydrat, fremgangsmate for fremstilling og bruk derav - Google Patents

Krystallform av besipirdinklorhydrat, fremgangsmate for fremstilling og bruk derav

Info

Publication number
NO20084010L
NO20084010L NO20084010A NO20084010A NO20084010L NO 20084010 L NO20084010 L NO 20084010L NO 20084010 A NO20084010 A NO 20084010A NO 20084010 A NO20084010 A NO 20084010A NO 20084010 L NO20084010 L NO 20084010L
Authority
NO
Norway
Prior art keywords
chlorohydrate
preparation
shows
following
crystal form
Prior art date
Application number
NO20084010A
Other languages
English (en)
Norwegian (no)
Inventor
Hugues Bienayme
Jacques Ferte
Original Assignee
Urogene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogene filed Critical Urogene
Publication of NO20084010L publication Critical patent/NO20084010L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20084010A 2006-02-20 2008-09-19 Krystallform av besipirdinklorhydrat, fremgangsmate for fremstilling og bruk derav NO20084010L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0601468A FR2897614B1 (fr) 2006-02-20 2006-02-20 Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations
US78715706P 2006-03-30 2006-03-30
PCT/IB2007/001456 WO2007096777A2 (fr) 2006-02-20 2007-02-20 Forme cristalline du chlorhydrate de besipirdine, procédé de préparation et utilisation de celle-ci

Publications (1)

Publication Number Publication Date
NO20084010L true NO20084010L (no) 2008-11-19

Family

ID=37309765

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084010A NO20084010L (no) 2006-02-20 2008-09-19 Krystallform av besipirdinklorhydrat, fremgangsmate for fremstilling og bruk derav

Country Status (16)

Country Link
US (1) US20090048304A1 (fr)
EP (1) EP1996575A2 (fr)
JP (1) JP2009527544A (fr)
KR (1) KR20080106232A (fr)
CN (1) CN101384584A (fr)
AU (1) AU2007219157A1 (fr)
BR (1) BRPI0707997A2 (fr)
CA (1) CA2642687A1 (fr)
FR (1) FR2897614B1 (fr)
IL (1) IL193191A0 (fr)
MA (1) MA30220B1 (fr)
MX (1) MX2008010659A (fr)
NO (1) NO20084010L (fr)
RU (1) RU2008133759A (fr)
WO (1) WO2007096777A2 (fr)
ZA (1) ZA200806876B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925355T3 (es) * 2017-07-03 2022-10-17 Shandong Danhong Pharmaceutical Co Ltd Forma cristalina y forma amorfa de clorhidrato análogo de dezocina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
ATE218343T1 (de) * 1995-07-27 2002-06-15 Aventis Pharma Inc Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva
AR046041A1 (es) * 2003-10-03 2005-11-23 Aventis Pharma Inc Procedimiento para la preparacion de compuestos heterociclicos n-amino sustituidos

Also Published As

Publication number Publication date
CA2642687A1 (fr) 2007-08-30
ZA200806876B (en) 2009-10-28
EP1996575A2 (fr) 2008-12-03
MA30220B1 (fr) 2009-02-02
WO2007096777A2 (fr) 2007-08-30
US20090048304A1 (en) 2009-02-19
JP2009527544A (ja) 2009-07-30
FR2897614B1 (fr) 2008-05-23
CN101384584A (zh) 2009-03-11
KR20080106232A (ko) 2008-12-04
FR2897614A1 (fr) 2007-08-24
WO2007096777A3 (fr) 2008-01-17
IL193191A0 (en) 2009-08-03
AU2007219157A1 (en) 2007-08-30
BRPI0707997A2 (pt) 2011-05-17
RU2008133759A (ru) 2010-03-27
MX2008010659A (es) 2008-09-01

Similar Documents

Publication Publication Date Title
WO2006122186A3 (fr) Derives de 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone utilises dans le traitement de l'hypercholesterolemie
WO2003093269A3 (fr) Pyrazolopyrimidine-4-one substituee
WO2008062276A3 (fr) Dérivés d'acétylène comme inhibiteurs de la stéaroyl coa désaturase
NO20075809L (no) DNA-PK inhibitorer
WO2008084223A3 (fr) Composés chimiques 637
HK1113352A1 (en) Chemical compounds
PL1853588T3 (pl) Związki chemiczne
WO2005074607A3 (fr) Procede de traitement de maladies hemolytiques
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
WO2005110994A3 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
WO2006104826A3 (fr) Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
TNSN06397A1 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20070608L (no) Anvendelse av 2-tio-3,5-dicyano-4-fenyl-6-aminopyridiner ved behandling av kvalme og oppkast
WO2006100082A3 (fr) Derives d'oxindole substitues, medicaments contenant ces derives et leur utilisation
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
WO2007030361A3 (fr) Composes de benzimidazole thiophene
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20082909L (no) Fremgangsmate for a utvinne lignan-ekstrakter og sammensetninger inneholdende lignan-ekstraktene
WO2002066035A3 (fr) Azoles en inhibiteurs de la décarboxylase des malonyl-coa, convenant comme modulateurs métaboliques
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20060718L (no) Substituerte tiofoner og deres anvendelse
EA200601295A1 (ru) Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application